Market Place
Sourcing Support
Immunitas Presents IMT-380 Preclinical Data at FASEB
30 Jul 2025 //
PR NEWSWIRE
Immunitas Therapeutics Presents Data at the AACR 2024 Annual Meeting
08 Apr 2024 //
PR NEWSWIRE
Immunitas to Present Preclinical Data Supporting Combination of IMT-009
05 Mar 2024 //
PR NEWSWIRE
Immunitas Appoints Annalisa D`Andrea, Ph.D., as Chief Scientific Officer
18 Jan 2024 //
PR NEWSWIRE
Immunitas Therapeutics Announces Appointment of James Wooldridge as CMO
04 Dec 2023 //
PR NEWSWIRE
Immunitas Therapeutics Presents New Data for TLR9 Agonist Conjugate
03 Nov 2023 //
PR NEWSWIRE
Immunitas Presents Data for Novel Anti CLEC2D-TLR9 Conjugate Program
31 Oct 2023 //
PR NEWSWIRE
Immunitas Announces First Patient Dosed in Phase 1/2a Study of IMT-009
04 Jan 2023 //
PR NEWSWIRE
Immunitas to Present Preclinical Data on IMT-009 at the 2022 SITC Annual Meeting
05 Oct 2022 //
PRNEWSWIRE
Immunitas Therapeutics Receives FDA Clearance of IND Application for IMT-009
21 Sep 2022 //
PRNEWSWIRE
Beijing CRO expands agreement with Merck; Early-stage venture firm closes fund
25 Aug 2022 //
ENDPTS
Immunitas Therapeutics Appoints Lynette Herscha as Chief Operating Officer
13 Jul 2022 //
PRNEWSWIRE
Immunitas` chief dealmaker steps up to CEO role
17 Nov 2021 //
ENDPTS
Lonza and Immunitas Therapeutics Announce Manufacturing Agreement
15 Apr 2021 //
PRESS RELEASE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.